// App-Quantinova.ai

980 : Prognostic Analyses for Adult Relapsed / Refractory Acute Lymphoblastic Leukemia Patients Who Received First Allogenic Hematopoietic Stem Cell Transplantation

Researchers

Presenter

  • Momoko Nakamura

Principal Investigators

  • Yasuyuki Arai

  • Shigeki Hirabayashi

  • Tadakazu Kondo

  • Noriko Doki

  • Naoyuki Uchida

  • Takahiro Fukuda

  • Yukiyasu Ozawa

  • Masatsugu Tanaka

  • Makoto Onizuka

  • Tatsuo Ichinohe

  • Yoshiko Atsuta

  • Shinichi Kako

Medical Centers

  • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

  • Department of Gastroenterology, Graduate School of Medicine Kobe University, Kobe, Japan

  • Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

  • Department of Medicine, Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital, Tokyo, Japan

  • Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital,

  • Department of Pediatrics, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan

  • of Hematology, Kanagawa Cancer Center, Yokohama, Japan

  • Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan

  • Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

  • Japanese Data Center for Hematopoietic Cell Transplantation,

  • Division of Rheumatology, Jichi Medical University Saitama Medeical Center, Saitama City, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

Biomarkers

  • Breakpoint Cluster Region

  • Ph chromosome

Drug/Treatment

  • Allopurinol

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved